The Impact of Multiple Sclerosis on Neurons: Understanding Demyelination

Last updated on:

February 27, 2026

The human nervous system depends on precise, high-speed communication between neurons. At the core of this communication is a protective coating called the myelin sheath – a fatty layer that wraps around nerve axons and enables electrical signals to travel rapidly and efficiently throughout the brain and body. In Multiple Sclerosis (MS), the immune system attacks and destroys this sheath in a process called demyelination. The consequences unfold in stages – from slowed signals, to complete blockages, to permanent axonal damage – and together they explain why MS can be such a profoundly disabling condition.

What is the myelin sheath and why does it matter?
What is demyelination?
How demyelination disrupts neural signals
Stage 1: Slowed signal transmission
Stage 2: Complete signal blockage
Stage 3: Permanent axonal damage
Why MS is considered a progressive disease
The relationship between demyelination and disability

What is the myelin sheath and why does it matter?

To understand demyelination, it helps to first understand what myelin does. According to NCBI Bookshelf, myelin is a greatly extended and modified plasma membrane that wraps around nerve axons in a spiral fashion. In the central nervous system (CNS), it is produced by cells called oligodendrocytes. These myelin segments are not continuous – they are interrupted at regular intervals by exposed gaps called the nodes of Ranvier.

This design is what makes nerve signaling so fast. Rather than flowing continuously along the entire axon, electrical impulses jump from one node of Ranvier to the next – a mechanism known as saltatory conduction (from the Latin saltare, meaning “to jump”). As explained by Kenhub, myelin’s insulating properties prevent ion leakage across the neuron, ensuring the reliable long-distance transmission of impulses. Wikipedia’s entry on saltatory conduction notes that myelinated axons can propagate action potentials at up to 150 metres per second, compared to just 0.5-10 metres per second in unmyelinated fibres.

Myelin does more than speed up signals – it also provides metabolic and trophic support to the axon itself. Research published in Neuron notes that myelin produces a lipoprotein sheath that wraps axons, speeding conduction and providing critical metabolic and trophic support to neurons. This dual role – electrical and nutritional – is what makes myelin loss so consequential in MS.

What is demyelination?

Demyelination is the process by which the myelin sheath is damaged or destroyed. In MS, this occurs because the immune system mistakenly identifies myelin as foreign and launches an inflammatory attack against it. A key review published in PubMed Central explains that MS is generally considered an autoimmune disease in which autoreactive T cells enter the CNS from the peripheral circulation and trigger an inflammatory cascade resulting in demyelination and axonal loss. Cytotoxic CD8+ T cells are also increasingly implicated in directly driving the demyelination process.

The result is that previously insulated axons become stripped of their protective covering – referred to as “denuded” axons. Nature Scitable describes it clearly: myelin loss causes remarkable nerve dysfunction because nerve conduction can be slowed or blocked, resulting in damaged information networks between the brain and the body. The physical location of demyelinated lesions in the CNS determines which symptoms emerge, since different regions of the brain and spinal cord control different functions.

How demyelination disrupts neural signals

Stage 1: Slowed signal transmission

The first and most immediate consequence of demyelination is a significant reduction in conduction speed. Without an intact myelin sheath, the nerve impulse can no longer jump efficiently between nodes of Ranvier. Instead, it must travel in a much slower, continuous fashion along the exposed axon membrane. Healthline’s overview of demyelination explains that in an unmyelinated neuron, signals travel at 0.5 to 10 metres per second, while in a myelinated neuron, they can reach up to 150 metres per second – a difference of more than tenfold.

This slowing translates directly into symptoms. The NIH review of demyelination in MS explains that segmental demyelination results in conduction block or slowing through adaptive responses, notably modifications in the distribution of voltage-gated sodium channels along the denuded axon. While the nervous system tries to compensate by redistributing sodium channels, this adaptation is imperfect and energy-costly. Patients may experience numbness, tingling, muscle weakness, fatigue, or slowed reflexes – all consistent with signals that are arriving too slowly or inconsistently to be useful.

Interestingly, even minor stressors can worsen this slowing. A review in PMC on demyelinating disorders of the CNS describes a phenomenon called Uhthoff’s phenomenon, in which patients with MS experience a transient worsening of symptoms – such as visual blurring – during physical exertion or exposure to heat. This occurs because demyelinated axons are particularly sensitive to changes in body temperature, which can push already-impaired conduction closer to complete failure.

Stage 2: Complete signal blockage

As demyelination becomes more severe, the signal does not merely slow – it stops entirely. This is called conduction block: the complete failure of a nerve impulse to propagate along an axon. A landmark study published in the New England Journal of Medicine found that inflammatory mediators in MS can block nerve conduction at the nodes of Ranvier, where the axon is most exposed.

The functional impact of conduction block depends entirely on which neurons are affected. If motor pathways in the spinal cord are blocked, the result may be muscle paralysis or significant weakness in the limbs. If sensory pathways are involved, the affected area may lose all feeling. If the optic nerve is demyelinated – a condition called optic neuritis, which is often an early sign of MS – vision in one eye can become blurred or disappear temporarily. Research published in Acta Neuropathologica Communications lists a range of such deficits in MS patients, including paresthesia (abnormal sensations), dysesthesia (unpleasant sensations), weakness, and visual disturbances such as blurring, greying of vision, and blind spots in the visual field.

It is important to note that conduction block at this stage can, in some cases, be reversible. If inflammation subsides and some remyelination occurs, conduction may be partially restored. This is why patients in the relapsing-remitting form of MS can experience periods of recovery after a flare-up.

Stage 3: Permanent axonal damage

If demyelination persists over time, the consequences move beyond disrupted signalling into permanent structural destruction. The axon itself, which was previously protected and nourished by the myelin sheath, becomes progressively damaged. The NIH’s PubMed Central review states that if demyelination persists, the loss of trophic and metabolic support will lead to irreversible axonal damage and loss.

The cellular mechanism behind this is now well understood. Research in Nature Reviews Neuroscience explains that sustained influx of sodium ions through channels along the denuded axon drives a damaging reverse exchange of calcium into the axon interior. This calcium accumulation activates destructive enzymes – including proteases and calpains – that break down the axon’s internal structural proteins, ultimately causing the axon to degenerate. Once this occurs, the damage is irreversible: unlike the myelin sheath, which can sometimes be repaired through remyelination, axons that have undergone significant degeneration cannot regenerate effectively in the adult CNS.

A major review published in Neurotoxicity Research summarises this clearly: axonal degeneration is the major determinant of irreversible neurological disability in patients with MS. Axonal loss from disease onset can remain clinically silent for many years, and permanent neurological disability develops when a threshold of axonal loss is reached and the CNS’s compensatory reserves are exhausted. This explains the progression many MS patients experience: early in the disease, the brain compensates remarkably well, but eventually this capacity is overwhelmed.

Why MS is considered a progressive disease

The three-stage cascade – slowed conduction, complete blockage, permanent axonal loss – provides the neurological basis for understanding why MS tends to worsen over time. Early in the disease, particularly in the relapsing-remitting form, the myelin sheath can partially repair itself through remyelination, and symptoms may improve after each flare. However, research in Neuron notes that while some remyelination occurs, especially in the early stages of MS, it becomes increasingly limited in later progressive disease. There is also significant variation between individuals and even between lesions in a single person, making recovery inconsistent.

Over time, lesions become chronically active. A review in Frontiers in Immunology explains that in progressive MS, always-active lesions are associated with disordered neural circuit remodelling, grey matter atrophy, and poor clinical outcomes – and neurodegeneration, rather than acute inflammation, becomes the dominant process. The accumulation of irreversible axonal loss across the CNS is what drives the steady functional decline seen in secondary and primary progressive forms of MS.

This understanding has important clinical implications. Researchers writing in Acta Neuropathologica Communications argue that early intervention is essential: because axonal damage begins at disease onset and can remain invisible clinically for years, waiting for obvious symptoms before treating aggressively may allow irreversible neurological loss to accumulate silently. Modern MS management increasingly focuses not just on controlling inflammation during relapses, but on protecting axons from long-term degeneration.

The relationship between demyelination and disability

One of the most clinically significant findings in MS research is the direct link between axonal loss and disability. The NEJM study on axonal transection in MS lesions found that axonal destruction was present in all lesions examined, across patients ranging from two weeks to 27 years of disease duration. It proposed that a threshold of axonal loss is eventually reached, beyond which patients experience progressive neurological deterioration that does not recover – even between relapses.

Importantly, research published in Neurology confirms that although effective disease-modifying therapies can prevent inflammatory relapses, much of the disability accumulation in MS occurs independently of those relapses – driven instead by the gradual, ongoing degeneration of axons in chronically demyelinated regions. This is why the field is actively pursuing neuroprotective therapies: treatments designed not just to suppress immune attacks, but to shield neurons and axons from the downstream damage that demyelination sets in motion.

Understanding demyelination – and the sequence of neurological harm it triggers – is not merely an academic exercise. It forms the scientific foundation for evaluating disability, designing treatment strategies, and ultimately improving quality of life for the millions of people living with MS worldwide.

What do you think? Given that axonal damage in MS can silently accumulate long before symptoms become obvious, how should this influence the way we approach early diagnosis and treatment decisions? And as remyelination therapies continue to be developed, which stage of demyelination – slowed conduction, complete blockage, or axonal loss – do you think is the most critical to target first?

References

PDF 📄

The Impact of Multiple Sclerosis on Neurons: Understanding Demyelination

Table of Contents

What is the myelin sheath and why does it matter? 🔗

What is demyelination? 🔗

How demyelination disrupts neural signals 🔗

Stage 1: Slowed signal transmission 🔗

Stage 2: Complete signal blockage 🔗

Stage 3: Permanent axonal damage 🔗

Why MS is considered a progressive disease 🔗

The relationship between demyelination and disability 🔗